Topical Timolol for Infantile Hemangioma in Early Proliferative Phase

Exclusion Criteria

• •Patients \> 60 days of age
• •Complicated hemangiomas (life-threatening, function-threatening, or ulcerated)
• •Children who have previously received systemic, intra-lesional or topical corticosteroids, imiquimod, vincristine, alpha-interferon, propranolol or other beta blockers, PDL laser.
• •Patients with PHACES, LUMBAR, SACRAL or PELVIS syndrome.
• •Internal involvement hemangiomas (liver, GI tract, larynx)
• •Children with a personal history of asthma or cardiac conditions that may predispose to heart block.
• •Children with congenital birth defects
• •Children with Cancer (leukemia, sarcoma, neuroblastoma, retinoblastoma)
• •Children with a history of hypersensitivity to beta blockers or excipients.